Targeted Combined Therapy Using Palbociclib and Bevacizumab with LncRNA Biomarker Analysis for Advanced Solid Tumors Including Colorectal, Lung, Breast, and Ovarian Cancers

What this Trial Is About

Researchers are evaluating a new targeted therapy approach for solid tumors, including colorectal, lung, breast, and ovarian cancers. This trial focuses on combining two drugs, Palbociclib, a CDK46 inhibitor that disrupts cancer cell growth, and Bevacizumab, an anti-VEGF agent that blocks blood vessel formation supporting tumors. The study also investigates the role of Long Non-Coding RNAs LncRNAs as biomarkers to personalize treatment based on molecular profiles, aiming for improved outcomes and survival. Participants receive combined therapy with Palbociclib and Bevacizumab, tailored based on their LncRNA risk allele status and prior chemotherapy treatment. Four groups are formed carriers and non-carriers of the risk allele, each receiving either first-line combined therapy without prior chemotherapy or second-line therapy after chemotherapy. Palbociclib is given orally at 125 mg daily for 21 days every 28 days, while Bevacizumab is administered at 10 mgkg every 21 days. Throughout the study, patients undergo thorough assessments before and after treatment, including tumor progression, treatment response, survival rates, and thromboembolic events. Researchers also measure immune checkpoint expression and tumor proliferation markers over up to 60 months. The trial uses a randomized design with single masking to monitor the safety and effectiveness of this dual-targeted treatment strategy for solid tumors.

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA